Daniel Tassé

Daniel Tassé is the current CEO of DBV Technologies. Daniel has also served as the CEO and Chairman of Alcresta Therapeutics from March 2016 to November 2018. Prior to that, they were a Non Executive Director at HLS Therapeutics Inc. Bellerophon Therapeutics from February 2015 to March 2019.

Tassé has over 25 years of experience in the pharmaceutical and healthcare industries. Daniel has a proven track record in building and leading successful companies. Daniel has a passion for helping people with rare diseases and is dedicated to developing and commercializing novel enzyme-based products.

Daniel Tassé earned a Bachelor of Science in Biochemistry and Mathematics from Université de Montréal.

Michele F. Robertson - Chief Legal Officer, Pascal Wotling - Chief Technical Operations Officer & Chief Quality Officer, and Caroline Daniere - Chief Human Resources Officer & Chief of Staff report to Daniel Tassé.